Published in Bone Joint Res on March 01, 2016
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Prevention of venous thromboembolism. Chest (2001) 5.59
BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet (2006) 3.79
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells (2009) 2.57
The biology of fracture healing. Injury (2011) 2.26
Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med (2003) 2.22
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur Cell Mater (2012) 1.62
Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost (2002) 1.44
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol (2006) 1.18
Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol (1993) 1.17
The role of endogenous bone morphogenetic proteins in normal skeletal repair. Injury (2009) 1.13
The effects of heparin and low molecular weight heparins on bone. Thromb Res (2007) 1.11
IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl) (2008) 1.06
Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood (1996) 1.02
Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res (2000) 1.01
Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma (2011) 0.98
Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation. BMC Cell Biol (2010) 0.96
Heparin-induced spinal fractures. JAMA (1979) 0.91
The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost (1996) 0.90
Impaired mesenchymal stem cell differentiation and osteoclastogenesis in mice deficient for Igf2-P2 transcripts. Development (2010) 0.89
αB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. BMC Cancer (2013) 0.87
IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. Bone Res (2013) 0.87
Osteoblast-Specific Loss of IGF1R Signaling Results in Impaired Endochondral Bone Formation During Fracture Healing. J Bone Miner Res (2015) 0.86
Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb (2003) 0.86
IGF1 promotes osteogenic differentiation of mesenchymal stem cells derived from rat bone marrow by increasing TAZ expression. Biochem Biophys Res Commun (2013) 0.83
The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord (2011) 0.83
The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res (2012) 0.83
Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis. Am J Surg (1991) 0.82
Rationale for thromboprophylaxis in lower joint arthroplasty. Am J Orthop (Belle Mead NJ) (2007) 0.82
Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol (2013) 0.79
Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban. BMC Musculoskelet Disord (2016) 0.78
Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells. Vasa (2014) 0.78